Healthspan in the Open: Why Longevity Medicine Must Publish What It Measures

November 13, 2026

Healthspan in the Open: Why Longevity Medicine Must Publish What It Measures

By Renée-Marie Stephano, Founder and Chief Executive Officer, Global Healthcare Accreditation. Fourth in a series on longevity, healthspan and standards.

‍

Longevity medicine will earn lasting public trust only when the organizations that sell healthspan improvement publish the outcomes they measure, openly and completely, including the results that disappoint. Because healthspan is shaped largely outside the clinic, those outcomes must also be reported alongside the social and public health conditions that influence them.

‍

Where this series has brought us

The first article in this series, The Gateway Is Longevity, the Convergence Is Healthspan, argued that longevity is what brings people in, but healthspan is the outcome that matters. Healthspan is the number of years a person lives in good function before decline.

‍

The second, Building for Healthspan, argued that prevention and clinical care must operate as one system, and that success should be measured by function preserved over time.

‍

The third, The Missing Piece, argued that the field needs shared standards: clear definitions of a longevity program, independent classification of evidence, and a refusal to treat biomarkers of aging as validated clinical outcomes.

‍

Each article arrived at the same unfinished task. The field must show, in public, whether what it offers works. Evidence that stays inside an organization is not evidence the field can use.

‍

The evidence gap in longevity medicine

Longevity programs collect more data on each patient than most medical practices: laboratory panels, imaging, fitness testing, wearable data and repeated assessments over time. Very little of it reaches the scientific literature. Some organizations hesitate to share results because the results may not support their claims. That hesitation is the strongest argument for sharing.

‍

Medicine has learned this lesson before. In a landmark review of antidepressant trials registered with the U.S. Food and Drug Administration, 94% of published trials appeared positive, compared with 51% when all trials were counted [1]. Researchers have estimated that as much as 85% of investment in health research is wasted, in part because results go unpublished or are poorly reported [2]. When only favorable results are visible, patients, clinicians and payers make decisions on a distorted picture.

‍

Longevity medicine also faces a measurement problem. Many programs report changes in biomarkers, including measures of “biological age.” These measures are advancing quickly, but leading researchers in the field have concluded that they are not yet validated for individual clinical decisions [3, 4]. Surrogate measures have misled medicine before, even when they moved in the expected direction [5].

‍

There is also a limit on what the field can honestly promise. A 2024 analysis in Nature Aging found that gains in life expectancy have slowed in the longest-lived populations, and that survival to age 100 is unlikely to exceed 15% for women and 5% for men this century unless the biology of aging itself is slowed [6]. The credible promise of longevity medicine is more healthy years, and the credible proof is function, measured over time and reported openly.

‍

Healthspan is shaped mostly outside the clinic

People are living longer, but not healthier. Across 183 World Health Organization member states, the average gap between lifespan and healthspan was 9.6 years in 2019. In the United States, the gap was 12.4 years, the largest of any country studied [7].

‍

The forces that widen or close that gap are largely social and behavioral:

• Social connection. A meta-analysis of 148 studies found that people with stronger social relationships had a 50% greater likelihood of survival over the study periods [8].

• Income and place. In the United States, the gap in life expectancy between the richest 1% and the poorest 1% was 14.6 years for men and 10.1 years for women [9].

• Daily habits. Adults who maintained five low-risk lifestyle factors gained an estimated 14.0 years of life expectancy at age 50 for women and 12.2 years for men [10].

• Community. Populations with exceptional longevity, such as the mountain communities of Sardinia, reached advanced ages without longevity clinics [11]. Their experience points to physical activity built into daily life, family and community ties, and shared purpose [12].

‍

The social determinants of health, defined by the World Health Organization as the conditions in which people are born, grow, live, work and age, account for much of the difference in health between groups [13, 14]. A clinic outcome reported without that context cannot be interpreted. Did a patient’s function improve because of an intervention, or because they retired, moved closer to family or started walking with friends every morning? Without context, no one can say.

‍

This does not reduce the role of clinical care. It defines it. Longevity medicine is most valuable when it works with the public health factors that build healthspan, and when its results are reported in a way that public health can use.

‍

A call for open outcomes

Every organization that sells healthspan should be prepared to show, in public, what happened to the people who bought it. We call on longevity programs, their medical leaders and the scientists who study aging to commit to six principles:

‍

1. Measure what matters to patients. Report function, disease-free years and quality of life, not only biomarkers. Gait speed, grip strength and cardiorespiratory fitness are simple, validated measures that predict survival [15, 16, 17].

2. Count everyone. Report outcomes for every person who begins a program, including those who leave it, not only the best cases.

3. Record the context. Collect social connection, living situation and access factors alongside clinical data, so results can be read honestly.

4. Use common definitions. Use shared measures and data definitions so that results from different organizations can be combined and compared [18].

5. Invite independent analysis. Allow qualified, independent researchers to analyze pooled outcomes, and report them using established standards for observational research [19].

6. Publish, whatever the result. Make findings available in the open scientific literature, with patient privacy and consent protected. Leading medical journals already expect clinical researchers to state how their data will be shared [20].

‍

Open outcomes protect patients, but they also protect the field. A program that publishes modest, honest results earns more credibility than one that markets dramatic claims it cannot support.

‍

Why open outcomes are a public health matter

Today, most longevity care is purchased privately and concentrated among people who can afford it. Open outcomes turn that private spending into public knowledge. When results are published, what works for a few can inform prevention for many.

‍

The potential gains are large. One analysis estimated that delaying aging would add 2.2 years of life expectancy, most of them healthy, with an economic value of $7.1 trillion over 50 years [21]. Another estimated that a slowdown in aging that adds one year of life expectancy is worth $38 trillion [22]. These are population-level benefits, and they depend on population-level evidence.

‍

Open data resources already show what is possible. Demographers, for example, have long relied on freely available mortality data to study how long populations live [23]. Longevity medicine needs the same commitment to openness if it is to show how well people live.

‍

Employers, insurers and health systems are increasingly asked to pay for longevity services. They need published, comparable outcomes before they can make responsible decisions. So do patients.

‍

The role of accreditation

Accreditation does not decide whether an intervention works. That is the role of science. What accreditation can do is set the conditions that make scientific answers possible.

‍

GHA’s Longevity Accreditation is built on this principle. Accredited organizations classify evidence independently, govern their claims, measure outcomes in a common way, and record the context in which care is delivered. The program is designed so that accredited organizations can contribute de-identified outcomes to independent analysis and publication. Participation begins on a voluntary basis during the pilot, with the expectation that open outcomes will become a mark of credibility in the field.

‍

What we ask of the field

‍

• Longevity programs: commit to measuring function, counting every patient and publishing results.

• Scientists and public health researchers: help define the outcome measures and lead independent analysis.

• Employers, insurers and health systems: ask for published outcomes before you buy.

• Patients: ask every program one question: “What happened to people like me?”

‍

Longevity brings people to the door. Healthspan is what they came for. Open outcomes are how the field proves it can deliver.

‍

Frequently asked questions

‍

What is healthspan?

Healthspan is the number of years a person lives in good health and function before the onset of chronic disease or disability.

‍

Why should longevity clinics publish their outcomes?

Publication lets patients, clinicians, payers and researchers see what works and what does not. Without it, decisions rest on marketing claims and selected success stories.

‍

Which outcomes should longevity programs report?

Programs should report measures of function, such as gait speed, grip strength and cardiorespiratory fitness, along with disease-free years and quality of life. Biomarkers alone, including biological age scores, are not validated outcomes.

‍

How do social determinants of health affect healthspan?

Social connection, income, education, living conditions and daily habits strongly influence how many years people live in good health. Outcomes should be reported with this context so results can be interpreted accurately.

‍

Does GHA accreditation certify that longevity treatments work?

No. GHA accreditation assesses how an organization classifies evidence, governs its claims, protects patients and measures outcomes. Whether a treatment works is a question for science, answered through open, published evidence.

‍

References

1. Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med. 2008;358(3):252-260.

2. Chalmers I, Glasziou P. Avoidable waste in the production and reporting of research evidence. Lancet. 2009;374(9683):86-89.

3. Moqri M, Herzog C, Poganik JR, et al. Biomarkers of aging for the identification and evaluation of longevity interventions. Cell. 2023;186(18):3758-3775.

4. Moqri M, Herzog C, Poganik JR, et al. Validation of biomarkers of aging. Nat Med. 2024;30(2):360-372.

5. Fleming TR, DeMets DL. Surrogate end points in clinical trials: are we being misled? Ann Intern Med. 1996;125(7):605-613.

6. Olshansky SJ, Willcox BJ, Demetrius L, Beltrán-Sánchez H. Implausibility of radical life extension in humans in the twenty-first century. Nat Aging. 2024;4:1635-1642. doi:10.1038/s43587-024-00702-3

7. Garmany A, Terzic A. Global healthspan-lifespan gaps among 183 World Health Organization member states. JAMA Netw Open. 2024;7(12):e2450241. doi:10.1001/jamanetworkopen.2024.50241

8. Holt-Lunstad J, Smith TB, Layton JB. Social relationships and mortality risk: a meta-analytic review. PLoS Med. 2010;7(7):e1000316.

9. Chetty R, Stepner M, Abraham S, et al. The association between income and life expectancy in the United States, 2001-2014. JAMA. 2016;315(16):1750-1766.

10. Li Y, Pan A, Wang DD, et al. Impact of healthy lifestyle factors on life expectancies in the US population. Circulation. 2018;138(4):345-355.

11. Poulain M, Pes GM, Grasland C, et al. Identification of a geographic area characterized by extreme longevity in the Sardinia island: the AKEA study. Exp Gerontol. 2004;39(9):1423-1429.

12. Buettner D, Skemp S. Blue Zones: lessons from the world’s longest lived. Am J Lifestyle Med. 2016;10(5):318-321.

13. Commission on Social Determinants of Health. Closing the Gap in a Generation: Health Equity Through Action on the Social Determinants of Health. Geneva: World Health Organization; 2008.

14. Marmot M. Social determinants of health inequalities. Lancet. 2005;365(9464):1099-1104.

15. Studenski S, Perera S, Patel K, et al. Gait speed and survival in older adults. JAMA. 2011;305(1):50-58.

16. Leong DP, Teo KK, Rangarajan S, et al. Prognostic value of grip strength: findings from the Prospective Urban Rural Epidemiology (PURE) study. Lancet. 2015;386(9990):266-273.

17. Kodama S, Saito K, Tanaka S, et al. Cardiorespiratory fitness as a quantitative predictor of all-cause mortality and cardiovascular events in healthy men and women: a meta-analysis. JAMA. 2009;301(19):2024-2035.

18. Wilkinson MD, Dumontier M, Aalbersberg IJ, et al. The FAIR Guiding Principles for scientific data management and stewardship. Sci Data. 2016;3:160018.

19. von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007;370(9596):1453-1457.

20. Taichman DB, Sahni P, Pinborg A, et al. Data sharing statements for clinical trials: a requirement of the International Committee of Medical Journal Editors. N Engl J Med. 2017;376(23):2277-2279.

21. Goldman DP, Cutler D, Rowe JW, et al. Substantial health and economic returns from delayed aging may warrant a new focus for medical research. Health Aff (Millwood). 2013;32(10):1698-1705.

22. Scott AJ, Ellison M, Sinclair DA. The economic value of targeting aging. Nat Aging. 2021;1(7):616-623.

23. Human Mortality Database. University of California, Berkeley (USA), and Max Planck Institute for Demographic Research (Germany). Available at www.mortality.org.

 

‍

Renée-Marie Stephano is Founder and Chief Executive Officer of Global Healthcare Accreditation and co-founder of the Longevity Vanguard, an invitation-only coalition that brings together longevity clinics, the companies that serve them, and the employers, insurers and investors who buy from them. A recognized standard setter in medical tourism, she co-developed the Medical Tourism Index and now leads GHA’s work in longevity and regenerative medicine accreditation. She has spoken at more than 100 events and has been featured in more than 250 publications. Learn more about the Longevity Vanguard.

 

‍

Testimonials

Andrea Maggioni, MD, PhD, MBA
Director, Global Health, Nicklaus Children's Hospital
Alejandro Cambiaso MD, MBA,
President, Médico Express San Isidro
Dr. Juan Luis Giraldo
‍International Director, Inser